Search

Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.

• News

Financial support for young people attending conference

• News

Volunteers are highly valued members of the Retina UK team and essential to our ability to achieve our vision of a world where all those affected by inherited retinal conditions are able to live a fulfilling life.

Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.

• Look Forward
• Audio
• Written

The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.

• Look Forward
• Audio
• Written

Are you affected by inherited sight loss? We are here to help.

X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.

Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.

• News

Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.

• News
• Usher syndrome

As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.

• News